Liquidia Corp
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Liquidia Corp
42.07
+0.22 · +0.53%
−10.52%
vs ±11.9% implied · ×0.89
shaded = implied · ▲▼ = realized
Linked news
Bull2
Bear2
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $860.2M | 13.50% | +96.54% |
| Farallon | $666.9M | 10.47% | new |
| Caligan Partners | $647.3M | 10.16% | 0.00% |
| Findell | $382.9M | 6.01% | +35.19% |
| Vanguardindex-like | $250.3M | 3.93% | +7.25% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $860.2M | 13.50% | +96.54% |
| Farallon | $666.9M | 10.47% | new |
| Caligan Partners | $647.3M | 10.16% | 0.00% |
| Findell | $382.9M | 6.01% | +35.19% |
| Vanguardindex-like | $250.3M | 3.93% | +7.25% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Liquidia Corp's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Liquidia Corp's 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Expected move
Inputs8Q avg ±7.4%·×0.56·cheap
straddle ±11.1%
spot 41.85exp Nov 13ATM strike 42ATM straddle 5.48IV 94%